AKR1C2 and breast carcinoma: The present study confirmed the previously observed downregulation of AKR1C2 (and 1C1 and 1C3) in breast tumors compared with nonneoplastic tissues.31,32 Our study, however, does not comply with the previously published data showing that AKR1C2 inhibition by 5β-cholanic acid restored sensitivity of adriamycin-resistant human breast adenocarcinoma cell line breast tumor cells in vitro.33 We detected AKR1C2 protein in breast carcinomas underlining a potentially functional role of AKR1C2 there.